ATE345805T1 - CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT - Google Patents

CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT

Info

Publication number
ATE345805T1
ATE345805T1 AT02764607T AT02764607T ATE345805T1 AT E345805 T1 ATE345805 T1 AT E345805T1 AT 02764607 T AT02764607 T AT 02764607T AT 02764607 T AT02764607 T AT 02764607T AT E345805 T1 ATE345805 T1 AT E345805T1
Authority
AT
Austria
Prior art keywords
calcium
medicaments
trifluorocetate
cytotoxic effect
tumor
Prior art date
Application number
AT02764607T
Other languages
German (de)
Inventor
Alberto Bartorelli
Original Assignee
Bionest Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionest Ltd filed Critical Bionest Ltd
Application granted granted Critical
Publication of ATE345805T1 publication Critical patent/ATE345805T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Calcium salts, in particular calcium trifluoroacetate, are added to medicaments to provide cytotoxic and antitumoral activity. The medicaments can be administered to cancer patients as part of a method of treating a cancer patient. The medicaments can also be applied to a tumor to treat the tumor. The medicaments may be administered or applied orally or parenterally.
AT02764607T 2001-07-12 2002-07-01 CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT ATE345805T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001495A ITMI20011495A1 (en) 2001-07-12 2001-07-12 CALCIUM SALTS WITH CYTOTOXIC ACTIVITY

Publications (1)

Publication Number Publication Date
ATE345805T1 true ATE345805T1 (en) 2006-12-15

Family

ID=11448051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764607T ATE345805T1 (en) 2001-07-12 2002-07-01 CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT

Country Status (10)

Country Link
US (1) US7423063B2 (en)
EP (1) EP1423131B1 (en)
JP (1) JP4395368B2 (en)
AT (1) ATE345805T1 (en)
CA (1) CA2455710C (en)
DE (1) DE60216292T2 (en)
ES (1) ES2277620T3 (en)
IL (2) IL159770A0 (en)
IT (1) ITMI20011495A1 (en)
WO (1) WO2003006031A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040665A1 (en) * 2004-04-02 2004-07-02 Pharmaproducts Uk Ltd SOCCER ROOMS FOR THE TREATMENT OF PSORIASIS AND DERMATITIS
ITMI20041279A1 (en) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd USE OF TRIFLUOROACETATE CALCIUM FOR THE PREPARATION OF ANTI-ANGIOGENETIC EFFECT MEDICATIONS
ITMI20041822A1 (en) * 2004-09-24 2004-12-24 Pharmaproducts Uk Ltd "USEFUL THERAPEUTIC AGENT FOR THE TREATMENT OF PLASMACELLULAR NEOPLASIES"
EP2796135A1 (en) 2013-04-22 2014-10-29 Polichem S.A. Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia
EP2845591A1 (en) 2013-09-04 2015-03-11 Polichem S.A. Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions
KR101683635B1 (en) 2014-12-29 2016-12-09 가천대학교 산학협력단 Pharmaceutical composition for treating cancer comprising lactate metallic salts
EA202091446A1 (en) 2018-01-12 2021-01-29 Метимеди Фармасьютикалз Ко., Лтд. METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636564A (en) * 1984-11-13 1987-01-13 Board Of Trustees Of The University Of Alabama 5-cyanopyridine-2-diazohydroxide, basic salts and methods for production and use
US4880660A (en) * 1987-08-28 1989-11-14 Minnesota Mining And Manufacturing Company Method for priming hard tissue
US5250545A (en) * 1988-02-12 1993-10-05 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitor methods
CN1058390C (en) * 1993-10-15 2000-11-15 伊莱利利公司 Methods for exhibiting angiogenisis and angiogenic diseases
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
EP1423131B1 (en) 2006-11-22
JP2004536120A (en) 2004-12-02
ITMI20011495A0 (en) 2001-07-12
CA2455710A1 (en) 2003-01-23
WO2003006031A1 (en) 2003-01-23
ES2277620T3 (en) 2007-07-16
ITMI20011495A1 (en) 2003-01-12
US20040180956A1 (en) 2004-09-16
US7423063B2 (en) 2008-09-09
IL159770A0 (en) 2004-06-20
DE60216292T2 (en) 2007-08-30
EP1423131A1 (en) 2004-06-02
IL159770A (en) 2009-09-22
CA2455710C (en) 2012-08-28
JP4395368B2 (en) 2010-01-06
DE60216292D1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
DE60023476D1 (en) COMBINATION OF DOCTAXEL AND RHUMAB HER2 FOR CANCER TREATMENT
CY1108629T1 (en) Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
EG25822A (en) Quinolinyl-pyrrolopyrazoles
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
NO20032027L (en) Effective anti-tumor treatments
BR0213906A (en) Methods for producing an anti-angiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and for treating cancer in a warm-blooded animal, pharmaceutical composition, kit, and use of zd6474 or one thereof pharmaceutically acceptable salt and a taxane
BR0313117A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect in a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and , use of zd6474 or a pharmaceutically acceptable salt thereof and zd1839 or a pharmaceutically acceptable salt thereof
MY164077A (en) Compositions and uses of et743 for treating cancer
BR0313116A (en) Method for producing a vascular and / or antiangiogenic permeability reducing effect on a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, and use of zd6474 or a pharmaceutically acceptable salt thereof.
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
ATE345805T1 (en) CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT
DE60116075D1 (en) TREATMENT OF TUMORS WITH PHOTODYNAMIC THERAPY
DE50100833D1 (en) USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND / OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS FOR PRODUCING A MEDICINE FOR TREATING CANCER DISEASES
ATE330600T1 (en) COMBINATION PREPARATION FOR CANCER THERAPY
ATE545423T1 (en) AGENTS FOR THE TREATMENT OF LUNG CANCER
EE200200549A (en) Split dose therapy with vascular damaging activity
FI20010233A0 (en) A method for treating heart failure
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
BRPI0407301A (en) Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.
DE60308403D1 (en) COMBINATION THERAPY WITH GEMZITABIN AND ZD6126

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1423131

Country of ref document: EP

EEIH Change in the person of patent owner